PAVE Home

Frequently Asked Questions

What is PAVE?

PAVE stands for Partnership for AIDS Vaccine Evaluation. PAVE is a voluntary consortium of United States Government (USG) agencies and key USG-funded organizations involved in the conduct of HIV vaccine clinical trials.

What are the goals of PAVE?

PAVE's goal is to provide a forum and clearinghouse to achieve better harmony, increased efficiencies and increased cost effectiveness in the conduct of HIV/AIDS preventive HIV vaccine trials, especially phase III trials.

Why is PAVE needed?

No one entity or institution will accomplish the goal of identifying a safe and effective HIV vaccine. Speed is critical and different expertises and sectors are required. Unnecessary duplication also needs to be avoided/eliminated. The bottom line is that there is an urgent need to increase efficiency and improve effectiveness.

How is PAVE organized?

PAVE is a voluntary consortium of USG agencies and key USG-funded organizations involved in the conduct of HIV vaccine clinical trials. PAVE membership consists of Partners and Affiliates. PAVE Partners include representatives from the National Institutes of Health (NIH): National Institute of Allergy and Infectious Diseases (NIAID) Division of AIDS (DAIDS), NIAID Dale and Betty Bumpers Vaccine Research Center (VRC), DAIDS HIV Vaccine Trials Network (HVTN), NIH Office of AIDS Research (OAR), and the NIH AIDS Vaccine Research Working Group; as well as representatives from the Centers for Disease Control and Prevention (CDC), the U.S. Military HIV Research Program (USMHRP) of the Department of Defense (DoD) and US Agency for International Development (USAID). PAVE Affiliates include representatives from U.S. government and non-U.S. government organizations that are dedicated to the goals of PAVE and meet certain criteria. Each is dedicated to evaluating HIV/AIDS preventive vaccines in clinical trials. Each maintains its independent identity. International AIDS Vaccine Initiative (IAVI) is a PAVE Affiliate member.

How is PAVE directed?

PAVE is led by an Executive Steering Group (ESG) whose role is to establish the goals and priorities of PAVE, determine how best to achieve PAVE goals, share preclinical and clinical data and plans, and establish and oversee working groups/chairs as needed.

Who is on the PAVE Executive Steering Group?

Representatives of the PAVE Partners comprise the PAVE Executive Steering Group (ESG). Included are:

Director, Vaccine and Prevention Research Program (VPRP), DAIDS/NIAID - Chair of the Executive Steering Group
Chief, Vaccine Clinical Research Branch (VCRB), DAIDS/ NIAID
Chair, AIDS Vaccine Research Advisory Working Group (AVRWG), DAIDS/NIAID
Principal Investigator, HIV Vaccine Trials Network (HVTN), DAIDS/NIAID
Director, United States Military HIV Research Program (USMHRP), Department of Defense (DOD)
Chief, Epidemiology Branch, Centers for Disease Control and Prevention (CDC)
Director, Vaccine Research Center (VRC), NIH/NIAID
Director, NIH Office of AIDS Research (OAR)
Representative, US Agency for International Development

What is expected of PAVE partners?

PAVE partners are expected to share strategic plans as well as preclinical and clinical results; collaborate on and/or compare results from clinical and laboratory evaluations; assist each other in the conduct of trial-associated activities where efficiencies in time and/or cost could result and participate in Working Groups as expertise permits.

Can other organizations join PAVE?

The PAVE Partners recognize that additional efficiencies in planning and operations might be achieved through the participation of other organizations that are willing to share strategic development plans and preclinical and clinical results. The PAVE Steering Group is currently considering how such membership will be structured in the future.

Are PAVE meetings open to the public?

As an ad hoc consortium comprised predominantly of USG employees, meetings of the PAVE ESG are not open to the public. However, PAVE Partners are keenly aware of the need to keep the public informed of its plans and activities and to ensure that its activities are more broadly coordinated with the efforts of others. To that end, the PAVE ESG updates the AIDS Vaccine Research Working Group, which holds public meetings 2-3 times a year, and PAVE partners participate regularly in other global coordination efforts.


Mission/Goals \| Areas of Collaboration \| Membership \| Working Groups \| FAQs \| Additional Links
Frequently Asked Questions What is PAVE? PAVE stands for Partnership for AIDS Vaccine Evaluation. PAVE is a voluntary consortium of United States Government (USG) agencies and key USG-funded organizations involved in the conduct of HIV vaccine clinical trials. What are the goals of PAVE? PAVE's goal is to provide a forum and clearinghouse to achieve better harmony, increased efficiencies and increased cost effectiveness in the conduct of HIV/AIDS preventive HIV vaccine trials, especially phase III trials. Why is PAVE needed? No one entity or institution will accomplish the goal of identifying a safe and effective HIV vaccine. Speed is critical and different expertises and sectors are required. Unnecessary duplication also needs to be avoided/eliminated. The bottom line is that there is an urgent need to increase efficiency and improve effectiveness. How is PAVE organized? PAVE is a voluntary consortium of USG agencies and key USG-funded organizations involved in the conduct of HIV vaccine clinical trials. PAVE membership consists of Partners and Affiliates. PAVE Partners include representatives from the National Institutes of Health (NIH): National Institute of Allergy and Infectious Diseases (NIAID) Division of AIDS (DAIDS), NIAID Dale and Betty Bumpers Vaccine Research Center (VRC), DAIDS HIV Vaccine Trials Network (HVTN), NIH Office of AIDS Research (OAR), and the NIH AIDS Vaccine Research Working Group; as well as representatives from the Centers for Disease Control and Prevention (CDC), the U.S. Military HIV Research Program (USMHRP) of the Department of Defense (DoD) and US Agency for International Development (USAID). PAVE Affiliates include representatives from U.S. government and non-U.S. government organizations that are dedicated to the goals of PAVE and meet certain criteria. Each is dedicated to evaluating HIV/AIDS preventive vaccines in clinical trials. Each maintains its independent identity. International AIDS Vaccine Initiative (IAVI) is a PAVE Affiliate member. How is PAVE directed? PAVE is led by an Executive Steering Group (ESG) whose role is to establish the goals and priorities of PAVE, determine how best to achieve PAVE goals, share preclinical and clinical data and plans, and establish and oversee working groups/chairs as needed. Who is on the PAVE Executive Steering Group? Representatives of the PAVE Partners comprise the PAVE Executive Steering Group (ESG). Included are: Director, Vaccine and Prevention Research Program (VPRP), DAIDS/NIAID - Chair of the Executive Steering Group Chief, Vaccine Clinical Research Branch (VCRB), DAIDS/ NIAID Chair, AIDS Vaccine Research Advisory Working Group (AVRWG), DAIDS/NIAID Principal Investigator, HIV Vaccine Trials Network (HVTN), DAIDS/NIAID Director, United States Military HIV Research Program (USMHRP), Department of Defense (DOD) Chief, Epidemiology Branch, Centers for Disease Control and Prevention (CDC) Director, Vaccine Research Center (VRC), NIH/NIAID Director, NIH Office of AIDS Research (OAR) Representative, US Agency for International Development What is expected of PAVE partners? PAVE partners are expected to share strategic plans as well as preclinical and clinical results; collaborate on and/or compare results from clinical and laboratory evaluations; assist each other in the conduct of trial-associated activities where efficiencies in time and/or cost could result and participate in Working Groups as expertise permits. Can other organizations join PAVE? The PAVE Partners recognize that additional efficiencies in planning and operations might be achieved through the participation of other organizations that are willing to share strategic development plans and preclinical and clinical results. The PAVE Steering Group is currently considering how such membership will be structured in the future. Are PAVE meetings open to the public? As an ad hoc consortium comprised predominantly of USG employees, meetings of the PAVE ESG are not open to the public. However, PAVE Partners are keenly aware of the need to keep the public informed of its plans and activities and to ensure that its activities are more broadly coordinated with the efforts of others. To that end, the PAVE ESG updates the AIDS Vaccine Research Working Group, which holds public meetings 2-3 times a year, and PAVE partners participate regularly in other global coordination efforts. Printable View
About PAVE \| Executive Steering Group \| Affiliate Membership \| Contact \| Home